Legend Biotech Q4 Earnings Call Highlights

Core Insights - The management of Legend Biotech emphasized the increasing utilization of CARVYKTI earlier in treatment courses, with approximately 65% of patients now treated in the second- to fourth-line settings [1][5] - CARVYKTI net trade sales reached approximately $555 million in Q4 2025, marking a 66% year-over-year increase, supported by share gains and site expansion [3][6] - The company achieved profitability for CARVYKTI in 2025 and anticipates enterprise-wide profitability in 2026 [4][21] Sales Performance - In the U.S., net trade sales were reported at $420 million, a 38% increase year-over-year and a 6% sequential rise, attributed to shipment seasonality [2] - Outside the U.S., sales reached $135 million, more than tripling compared to the prior year and increasing by 5% sequentially, with notable strength in Germany, Spain, and Belgium [2] Clinical Data and Treatment Efficacy - Clinical data indicated a median progression-free survival of 50.4 months for triple-class-exposed patients, with 65% of patients treated in the second- to fourth-line settings [5][7] - Long-term data presented at key meetings showed that 80% of standard-risk patients remained progression-free after 2.5 years, with 93% of those progression-free at one year remaining alive and progression-free at 2.5 years [8] Manufacturing and Capacity - Legend Biotech has established manufacturing capacity for 10,000 doses, with plans to expand to 20,000 doses in collaboration with Johnson & Johnson, achieving a manufacturing success rate of 97-99% [5][12][13] - The company reported improved gross margins, with a gross margin of 61% and a gross margin on CARVYKTI net product sales of 57% [15][14] Financial Results - The fourth-quarter revenue was reported at $306 million, a 64% increase year-over-year, with operating margin improving from -142% to -6% over ten consecutive quarters [15][17] - Legend Biotech ended the year with $949 million in cash and equivalents, with operating cash flow outlays significantly reduced from $82 million to $12 million year-over-year [18] Future Outlook - The company is committed to sequential growth throughout 2026, with management expressing confidence in achieving approximately 50% top-line growth year-over-year based on market consensus [19] - Investment priorities include advancing in vivo programs, supporting CARVYKTI profit expansion, and modest capital expenditures related to manufacturing [21]